A comprehensive view of Phase 3 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

US FDA accepts for priority review GSK’s application for an expanded indication of Jemperli (dostarlimab-gxly) plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer
Published: April 24, 2024 by GSK Group (GlaxoSmithKline)
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
Health Canada approves Merck & Co's KEYTRUDA in combination with chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma treatment following successful Phase 3 trial
Published: April 19, 2024 by EquityBites
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Eli Lilly reports tirzepatide injectable significantly reduced sleep apnea in Phase 3 trials, achieving up to 63% reduction in the apnea-hypopnea index, a measure of sleep apnea severity; the drug also led to significant weight loss
Published: April 17, 2024 by Eli Lilly & Co.

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count